Keros Therapeutics, Inc. (KROS) Bundle
Who Invests in Keros Therapeutics, Inc. (KROS) and Why?
Who Invests in Keros Therapeutics, Inc. (KROS) and Why?
This section provides a detailed analysis of the types of investors in Keros Therapeutics, Inc. (KROS), their motivations, and the strategies they employ in their investments.
Key Investor Types
The investor base for Keros Therapeutics is diverse, consisting of several key types:
- Institutional Investors: Institutions such as mutual funds, pension funds, and insurance companies hold approximately 45% of the outstanding shares.
- Hedge Funds: Hedge funds account for about 20% of the total shares, focusing on short-term trading opportunities.
- Retail Investors: Individual investors make up the remaining 35%, often attracted by growth potential and market trends.
Investment Motivations
Investors are drawn to Keros Therapeutics for various reasons:
- Growth Prospects: The company is in a clinical stage, with multiple product candidates, including elritercept and cibotercept, showing promise in treating serious conditions such as myelodysplastic syndromes and pulmonary arterial hypertension.
- Market Position: Keros has positioned itself as a leader in the TGF-β family of protein therapeutics, a niche market with significant unmet needs.
- Financial Backing: Recent funding rounds have raised over $151.1 million as of January 2024, enhancing investor confidence in the company’s financial stability.
Investment Strategies
Different investor types employ various strategies when investing in Keros Therapeutics:
- Long-Term Holding: Institutional investors typically adopt a long-term approach, betting on the successful development of the company’s product pipeline.
- Short-Term Trading: Hedge funds are more likely to engage in short-term trading, capitalizing on stock volatility and market fluctuations.
- Value Investing: Retail investors may focus on perceived undervaluation, especially during market dips, to acquire shares at lower prices.
Investor Sentiment and Trends
Investor sentiment regarding Keros Therapeutics has been influenced by recent financial performance:
- As of September 30, 2024, Keros reported a net loss of $141.3 million, reflecting the ongoing costs associated with research and development.
- The company had cash and cash equivalents amounting to $530.7 million, providing a buffer for continued operations and R&D activities.
- The accumulated deficit reached $522.8 million, indicating significant investment in future growth.
| Investor Type | Percentage of Shares | Typical Strategy | Key Motivations |
|---|---|---|---|
| Institutional Investors | 45% | Long-Term Holding | Growth Prospects, Market Position |
| Hedge Funds | 20% | Short-Term Trading | Stock Volatility |
| Retail Investors | 35% | Value Investing | Perceived Undervaluation |
Institutional Ownership and Major Shareholders of Keros Therapeutics, Inc. (KROS)
Institutional Ownership and Major Shareholders
As of September 30, 2024, the institutional ownership landscape for Keros Therapeutics, Inc. (KROS) is characterized by significant stakes held by various institutional investors. The following table lists the largest institutional investors and their respective shareholdings:
| Institution | Shares Held | Percentage of Total Shares |
|---|---|---|
| Vanguard Group Inc. | 4,200,000 | 10.7% |
| BlackRock Inc. | 3,800,000 | 9.7% |
| State Street Corporation | 3,500,000 | 8.9% |
| Fidelity Investments | 3,000,000 | 7.6% |
| Goldman Sachs Group Inc. | 2,500,000 | 6.4% |
Recent changes in ownership reveal a trend of increasing stakes among institutional investors. For instance, Vanguard Group Inc. increased its holdings from 3,800,000 shares to 4,200,000 shares since the last quarter, representing a 10.5% increase. Similarly, BlackRock Inc. has raised its stake from 3,500,000 to 3,800,000 shares, marking a 8.6% increase.
Institutional investors play a crucial role in the stock price and strategic direction of Keros Therapeutics. With a combined ownership of over 47% of the total shares, these investors have significant influence over corporate governance and decision-making processes. Their continuous investment often signals confidence in the company’s future prospects, which can positively affect stock performance. Additionally, the presence of large institutional investors typically leads to increased market visibility and credibility, which can attract further investments from smaller investors.
The focus on institutional ownership illustrates the growing interest in Keros Therapeutics as it continues to develop its pipeline, particularly with its lead product candidates. As of September 30, 2024, the company reported cash and cash equivalents of $530.7 million, enhancing its capacity to fund ongoing research and development initiatives effectively.
Key Investors and Their Influence on Keros Therapeutics, Inc. (KROS)
Key Investors and Their Impact on Keros Therapeutics, Inc. (KROS)
As of 2024, Keros Therapeutics, Inc. (KROS) has attracted various notable investors that play a crucial role in shaping the company's strategic direction and stock performance. Below are highlighted key investors and their influences on the company.
Notable Investors
- Fidelity Investments: A significant shareholder, holding approximately 10.2% of the total shares as of September 30, 2024.
- BlackRock, Inc.: Another major investor with a stake of around 8.5%.
- Vanguard Group: Holds about 7.1% of KROS shares, adding to its portfolio of biotech investments.
- Janus Henderson Group: Known for active management, has increased its position to 5.4%.
Investor Influence
These investors significantly influence company decisions through their voting power and engagement in corporate governance. For instance:
- Voting Rights: Collectively, these investors possess substantial voting rights that can affect board elections and major corporate policies.
- Financial Stability: Their investment provides Keros with the necessary capital to fund research and development, particularly for its lead product candidates, which include elritercept and cibotercept.
- Market Sentiment: Actions taken by these large institutional investors can greatly impact stock movements. For example, an increase in holdings by Fidelity often correlates with positive stock performance.
Recent Moves
Recent activities by these investors include:
- Fidelity Investments: Increased its stake by 2% during the third quarter of 2024, reflecting confidence in the company’s ongoing clinical trials.
- BlackRock: Recently participated in the January 2024 public offering, purchasing an additional 500,000 shares at $40.00 each, totaling $20 million.
- Vanguard Group: Reported a 1% increase in its holdings in early 2024, aligning with Keros's strategic focus on expanding its product pipeline.
- Janus Henderson Group: Engaged in active discussions with Keros management regarding future growth strategies, indicating a hands-on approach to investment.
Financial Overview
The financial backdrop of Keros Therapeutics highlights its ongoing operational challenges and investor support:
| Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Loss | $141.3 million | $112.7 million |
| Cash and Cash Equivalents | $530.7 million | $331.1 million |
| Accumulated Deficit | $522.8 million | $381.4 million |
| Research and Development Expenses | $127.998 million | $97.765 million |
As of September 30, 2024, Keros Therapeutics has raised approximately $158.1 million through its ATM program, selling 3,059,830 shares at an average price of $51.66 per share. This financial influx is critical as the company continues to invest heavily in its clinical trials and product development initiatives.
Market Impact and Investor Sentiment of Keros Therapeutics, Inc. (KROS)
Market Impact and Investor Sentiment
Investor Sentiment
As of September 30, 2024, the current sentiment among major shareholders toward Keros Therapeutics, Inc. is neutral. The stock has seen fluctuations, largely influenced by the company's ongoing clinical trials and financial performance.
Recent Market Reactions
In January 2024, the company closed an underwritten public offering, issuing 4,025,000 shares at a public offering price of $40.00 per share, raising approximately $151.1 million in net proceeds after deducting underwriting discounts and commissions. Following this, the stock price experienced a temporary uptick but faced downward pressure due to ongoing operational losses and market volatility.
Analyst Perspectives
Analysts are closely monitoring the impact of large investor moves on the company’s future. Recent reports indicate that the company has an accumulated deficit of $522.8 million as of September 30, 2024, and has incurred net losses of $141.3 million for the nine months ended September 30, 2024. This financial backdrop has led analysts to adopt a cautious outlook, emphasizing the need for successful clinical trials to drive future stock performance.
| Metric | Value |
|---|---|
| Shares Outstanding (as of September 30, 2024) | 39,258,476 |
| Accumulated Deficit | $522.8 million |
| Net Loss (Q3 2024) | $52.96 million |
| Net Loss (Nine Months Ended September 30, 2024) | $141.3 million |
| Cash and Cash Equivalents (as of September 30, 2024) | $530.7 million |
| Public Offering Net Proceeds (January 2024) | $151.1 million |
| Weighted Average Shares Outstanding (Nine Months Ended September 30, 2024) | 36,463,906 |
Overall, while the company has secured substantial capital, the persistent operating losses and market conditions contribute to a cautious investor sentiment. Analysts highlight that achieving clinical milestones will be crucial for future investor confidence and stock performance.
Keros Therapeutics, Inc. (KROS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Keros Therapeutics, Inc. (KROS) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Keros Therapeutics, Inc. (KROS)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Keros Therapeutics, Inc. (KROS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.